Walton Oaks, 30 July 2026 – Pfizer Ltd announced today the opening of its new Internal Medicine Innovation Center (IMIC) at the London BioScience Innovation Centre (LBIC): Apex, part of the UK’s thriving Knowledge Quarter. The state-of-the-art facility will work to accelerate early-stage research into peptide-based medicines. 

The centre builds on Pfizer’s acquisition of Metsera, bringing together UK scientists from this group with existing Pfizer researchers in one new location. The Internal Medicine Innovation Center (IMIC) will focus on the discovery and development of peptide-based therapeutics, contributing to Pfizer’s global pipeline of potential treatments for conditions such as obesity and cardiometabolic disease. 

This investment reflects the UK’s strength in early-stage scientific research and builds on Pfizer’s continued scientific presence in the UK - investing over £2.9bn in research and development in the UK since 2016.

The site will be home to highly skilled scientists who have industry-leading expertise in peptide-based drug discovery and have contributed to the development of obesity medicines in Pfizer’s current pipeline.

In addition to serving as a Pfizer UK research hub, the IMIC will endeavour to strengthen Pfizer’s relationships with UK academic institutions, including ongoing partnerships with Imperial College London and the Medical Research Council’s Laboratory of Medical Sciences (MRC).

Jonathan Reynolds, Secretary of State for Business, Innovation, Science and Trade:
“The UK life sciences industry is driving growth, jobs, and opportunity across the country - attracting more than £3 billion in public-private investment over the first year of our Industrial Strategy. 

 "Investment in early-stage research keeps the UK at the forefront of innovation.  

 “Today's announcement from Pfizer is yet more evidence of our world-leading scientific expertise - putting brilliant British research at the heart of efforts to discover new treatments that will save and improve lives.” 

Jim List, MD, PhD, Chief Internal Medicine Officer, Pfizer reiterated: "Obesity remains one of the most significant health challenges of our time, and Pfizer is committed to advancing the science needed to meet the diverse needs of people living with it. The new Internal Medicine Innovation Centre in London brings together some of our most talented researchers under one roof, with world-class capabilities in peptide discovery that strengthen our ability to investigate next-generation treatments.” 

John McGinley, Country President and Managing Director, Pfizer UK commented: “Today’s announcement is an important milestone for Pfizer UK and is testament to the leading science that takes place here. As UK scientists work to develop potential medicines of the future, we're committed to working with Government to ensure UK patients can ultimately benefit from these advances." 

Amanda Keightley-Pugh, Chief Commercial Officer, LBIC added: “We are delighted to welcome Pfizer's new Internal Medicine Innovation Center to LBIC: Apex. This investment is a strong endorsement of the UK's life sciences ecosystem and the collaborative environment we have built here within the Knowledge Quarter. By bringing together exceptional scientific talent and strengthening links with leading academic institutions, Pfizer's presence at LBIC will help foster innovation that has the potential to improve the lives of patients around the world. We look forward to supporting the team as they become part of our vibrant community." 

For all media enquiries, please contact:
Pfizer UK Press Office
Tel: 0845 300 8033
Email: pressofficeUK@pfizer.com

Notes to Editor 

Pfizer in the UK

Pfizer has had a presence in the UK for over 70 years, employing over 1,700 people and providing over 150 medicines to the NHS.  

Pfizer has contributed over £2.9bn in R&D in the UK since 2016. There are currently 77 Pfizer sponsored clinical trials on-going in the UK and in 2025 Pfizer contributed to 104 research collaborations with universities, pharmaceutical companies and others.  

About Pfizer: Breakthroughs That Change Patients’ Lives  
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at www.pfizer.co.uk or follow us on X (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).